1. Financial ties between authors of the clinical practice guidelines and pharmaceutical companies: an example from Japan.
- Author
-
Saito, H., Tani, Y., Ozaki, A., Sawano, T., Shimada, Y., Yamamoto, K., and Tanimoto, T.
- Subjects
- *
STAPHYLOCOCCUS aureus infections , *GUIDELINES , *METHICILLIN-resistant staphylococcus aureus - Abstract
The MRSA clinical practice guidelines, which include a recommended treatment for MRSA infections, could be considered important clinical practice guidelines for both clinicians and pharmaceutical companies in the area of infectious diseases. Surprisingly, some authors failed to accurately declare their financial conflicts of interest, and employees of anti-MRSA drug companies joined as the advisory authors of the MRSA clinical practice guidelines, suggesting significant negligence in the management of conflicts of interests. To the best of our knowledge no previous study has analysed the financial relationships of clinical practice guideline committee members of infectious diseases, and this study revealed for the first time that manufacturers of anti-MRSA drugs made large payments to Japanese MRSA clinical practice guidelines authors, totalling nearly €240 000. Hence, medical societies in Japan should carefully screen authors of clinical practice guidelines - including but not limited to the MRSA clinical practice guidelines - to improve their credibility among the general public. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF